Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

569 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
HER2-positive breast cancer cells resistant to trastuzumab and lapatinib lose reliance upon HER2 and are sensitive to the multitargeted kinase inhibitor sorafenib.
Valabrega G, Capellero S, Cavalloni G, Zaccarello G, Petrelli A, Migliardi G, Milani A, Peraldo-Neia C, Gammaitoni L, Sapino A, Pecchioni C, Moggio A, Giordano S, Aglietta M, Montemurro F. Valabrega G, et al. Among authors: milani a. Breast Cancer Res Treat. 2011 Nov;130(1):29-40. doi: 10.1007/s10549-010-1281-5. Epub 2010 Dec 9. Breast Cancer Res Treat. 2011. PMID: 21153051
Metastatic breast cancer subtypes and central nervous system metastases.
Aversa C, Rossi V, Geuna E, Martinello R, Milani A, Redana S, Valabrega G, Aglietta M, Montemurro F. Aversa C, et al. Among authors: milani a. Breast. 2014 Oct;23(5):623-8. doi: 10.1016/j.breast.2014.06.009. Epub 2014 Jun 30. Breast. 2014. PMID: 24993072 Free article.
Recent advances in the development of breast cancer vaccines.
Milani A, Sangiolo D, Aglietta M, Valabrega G. Milani A, et al. Breast Cancer (Dove Med Press). 2014 Oct 14;6:159-68. doi: 10.2147/BCTT.S38428. eCollection 2014. Breast Cancer (Dove Med Press). 2014. PMID: 25339848 Free PMC article. Review.
Buparlisib , an oral pan-PI3K inhibitor for the treatment of breast cancer.
Geuna E, Milani A, Martinello R, Aversa C, Valabrega G, Scaltriti M, Montemurro F. Geuna E, et al. Among authors: milani a. Expert Opin Investig Drugs. 2015 Mar;24(3):421-31. doi: 10.1517/13543784.2015.1008132. Epub 2015 Feb 3. Expert Opin Investig Drugs. 2015. PMID: 25645727 Review.
569 results